Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
NCT: NCT06329570 · SUSPENDED
広告
NCT識別子NCT06329570
ステータスSUSPENDED
開始日2024-10-22
完了2028-03-31
SponsorNaviFUS Corporation (INDUSTRY)
First posted
Last updated
概要
This will be a prospective, open-label, single-arm pilot study to investigate the safety and efficacy of Bevacizumab (BEV) in combination with microbubble (MB)-mediated FUS in patients with recurrent GBM. BEV represents the physician's best choice for the standard of care (SoC) in rGBM after previous treatment with surgery (if appropriate), standard radiotherapy with temozolomide chemotherapy, and with adjuvant temozolomide.
公式ソース
ClinicalTrials.govで見る →データはClinicalTrials.gov APIから取得しています。最新のステータスは公式記録をご確認ください。